SAD, BAD Or DAD? Insiders See Risks Increasing In China IO Rush
This article was originally published in PharmAsia News
More than 50 biotechs in China are now developing immuno-oncology assets centered mainly on the checkpoint inhibitor PD-1, meaning the emerging and promising treatment area is quickly becoming a crowded battlefield, insiders at a recent ChinaBio partnering event cautioned.
You may also be interested in...
Zai Lab Soars On Nasdaq Debut
Shanghai-based drug developer Zai Lab shares jumped on its first day of public trading, reflecting the strong interest in drug development in China.
Deal Watch: WuXi/Gloria License PD-1 Inhibitor To Arcus For Up To $816m
WuXi Biologics and Harbin Gloria will get $18.5m up front for the Phase I asset GLS-010. Also, Cerecor divests depression drug to Janssen for up to $45m and Perrigo sells its API division for $110m in cash.
2016 Review: Pricing, R&D Issues Dominate China Commercial Arena
2016 was again another busy year on the commercial front in China, with market changes, new regulations, and ongoing pricing pressures all affecting the pharma sector. Meanwhile, the push for licensing deals, innovation, and international expansion continued apace.